Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Elective Orthopedic Surgery
Interventions: Midazolam, Propofol, Saline; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions: Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection; Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Wound Infection
Interventions: Normal saline, Prontosan; Drug · Device
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Headache
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Healthy
Interventions: Atropine, Propranolol, Normal Saline; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Joint Replacement Surgery
Interventions: Normal Saline 10 mL Injection; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lumbosacral Radiculopathy
Interventions: etanercept, methylprednisolone, normal saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Fort Bragg, North Carolina

Conditions: Hip Pain Chronic, Hip Impingement Syndrome, Hip Injuries, Blood Loss, Femoro Acetabular Impingement
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Myocardial Infarction
Interventions: BB3, Normal saline; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New Haven, New York

Conditions: Intraoperative Neurophysiological Monitoring, Magnesium Sulfate
Interventions: Magnesium sulfate, Normal Saline; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nausea
Interventions: Ondansetron, Metoclopramide, Promethazine, Normal Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pain, Postoperative, Ankle Fractures
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Calciphylaxis
Interventions: EPN-701 (Oral), Placebo (Normal Saline); Drug
Lead sponsor: Sagar U. Nigwekar, MD, MMSc; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Suicide, Suicide Threat, Depression Severe
Interventions: Ketamine Hydrochloride, Normal saline; Drug
Lead sponsor: Naval Medical Center Camp Lejeune; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Marine Corps Base Camp Lejeune, North Carolina

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass (RYGB), Caloric Restriction, Exendin-9,39, Normal Saline; Procedure · Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoarthritis of the Knee
Interventions: FX006, Placebo, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more

Conditions: Propofol Injection Pain
Interventions: Passive arm elevation, Normal saline, Lidocaine, Propofol, Sham arm elevation; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Postoperative Pain Control in Surgical Neonates
Interventions: Ketorolac, placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Week to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain
Interventions: bupivacaine liposome injectable suspension, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more

Conditions: Cystic Fibrosis
Interventions: MRT5005, Normal saline; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more

Conditions: Respiratory Distress Syndrome, Adult, Head Injuries, Closed, Shock, Shock, Traumatic
Interventions: Hypertonic Saline-Dextran Solution, Lactated Ringer's Solution; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Search by objective public record fields.

Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication

Sublingual vs IV Atropine Bioavailability Study

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

Ketamine for Acute Migraine in the Emergency Department

Analysis of Atropine and Propranolol Induced Changes

Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

Tranexamic Acid (TXA) in Hip Arthroscopy

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring

Intravenous Ketamine for Treatment-Resistant Depression

Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

Study of EPN-701 for the Treatment of Calciphylaxis

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Arm Elevation for Prevention of Propofol Injection Pain

The Use of Ketorolac in Surgical Neonates

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)